We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




New QC Reagents Compatible with Multiple Immunoassay Platforms

By LabMedica International staff writers
Posted on 22 Sep 2019
Print article
Image: The new Acusera quality control reagents are designed for cost-effectiveness, as well as accurate and reproducible results (Photo courtesy of Randox).
Image: The new Acusera quality control reagents are designed for cost-effectiveness, as well as accurate and reproducible results (Photo courtesy of Randox).
A new set of infectious disease (serology) quality control reagents is designed to deliver a cost-effective, high-quality solution for the analysis of infectious diseases, while producing repeatable trustworthy results on various immunoassay platforms.

The Randox (Crumlin, United Kingdom) Quality Control Acusera Infectious Disease Serology Controls cover a wide range of infectious diseases, including HIV, hepatitis, EBV, CMV, Varicella zoster virus, ToRCH, Lyme disease and others. These controls are compatible for use on some of the most popular immunoassay platforms including Roche, Abbott, Siemens and Beckman among others.

The Acusera control reagents are manufactured from human plasma, and each control is designed to react to the test system in the same manner as the patient sample. The new controls meet ISO 15189:2012 requirements and reduce inconvenient shifts in QC results when reagent batches are changed.

The reagents, which have been optimized for use by microbiology and virology laboratories, blood banks, public health laboratories, and clinical laboratories performing serology testing, have working stability of 60 days.

Lynsey Adams, Quality Control Manager at Randox, said, “These controls are the first of their kind on the market to be used on a wide range of immunoassay analyzers. Unlike the current practice of analyzer-specific tests, these controls can be used across a wide range of laboratory technologies and, with a working stability of 60 days at two to eight degrees Celsius, waste and costs are kept to a minimum.”

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.